抑郁症治疗药物发展(3)
[8]Papakostas GI，Nelson JC，Kasper S，et al. A meta-analysis of clinical trials comparing reboxetine，a norepinephrine reuptake inhibitor，with selective serotonin reuptake inhibitors for the treatment of major depressive disorder[J].Eur Neuropsychopharmacol，2008，18(2)：122-127.
[9]Sunderland T，Cohen RM，Molchan S，et al. High-dose selegiline in treatment-resistant older depressive patients[J].Arch Gen Psychiatry，1994，51(8)： 607-615.
[10]Amsterdam JD，Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder：A 52-week，double-blind，placebo-substitution，parallel-group clinical trial[J].J Clin Psychopharmacol，2006，26(6)：579-586.
[11]Bauer M，Dopfmer S. Lithium augmentation in treatment-resistant depression：Meta-analysis of placebo-controlled studies[J].J Clin Psychopharmacol，1999，19(5)：427-434.
[12]Kennedy SH，Lam RW. Enhancing outcomes in the management of treatment resistant depression：A focus on atypical antipsychotics[J].Bipolar Disord，2003，5(Suppl 2)：36-47.
(收稿日期：2011-02-01), http://www.100md.com(姜玉龙 赵重波)
[9]Sunderland T，Cohen RM，Molchan S，et al. High-dose selegiline in treatment-resistant older depressive patients[J].Arch Gen Psychiatry，1994，51(8)： 607-615.
[10]Amsterdam JD，Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder：A 52-week，double-blind，placebo-substitution，parallel-group clinical trial[J].J Clin Psychopharmacol，2006，26(6)：579-586.
[11]Bauer M，Dopfmer S. Lithium augmentation in treatment-resistant depression：Meta-analysis of placebo-controlled studies[J].J Clin Psychopharmacol，1999，19(5)：427-434.
[12]Kennedy SH，Lam RW. Enhancing outcomes in the management of treatment resistant depression：A focus on atypical antipsychotics[J].Bipolar Disord，2003，5(Suppl 2)：36-47.
(收稿日期：2011-02-01), http://www.100md.com(姜玉龙 赵重波)